Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the prevention of pregnancy in women with uterine fibroids or endometriosis.
Relugolix Combination Tablet is not
approved by the FDA in the
prevention of pregnancy.
Recent News and Presentations
5 Aug 2022
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
27 Jul 2022
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.